Glutamate transporter activation enhances nicotine antinociception and attenuates nicotine analgesic tolerance

NeuroReport

Volumn 22, Issue 18, 2011, Pages 970-973

  Schroeder, Joseph A ^a   Quick, Katrina F ^a   Landry, Paige M ^a   Rawls, Scott M ^b  

^a The Holleran Center for Community Action and Public Policy   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

lactam; Analgesia; glutamate; glutamate transporter subtype 1; nicotine; tolerance

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; GLUTAMATE TRANSPORTER; NICOTINE; VESICULAR GLUTAMATE TRANSPORTER 1;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

AMINO ACID TRANSPORT SYSTEM X-AG; ANALGESICS; ANIMALS; CEFTRIAXONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; MALE; NICOTINE; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; TIME FACTORS;

EID: 81855221747     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32834d87eb     Document Type: Article

References (24)

1. Davis L, Pollock LJ, Stone TT. Visceral pain. Surg Gynecol Obstet 1932; 55:418-427
2. Decker MW, Rueter LE, Bitner RS. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr Top Med Chem 2004; 4:369-384. (Pubitemid 38842575)
3. Marks MJ, AC Collins. Tolerance cross-tolerance and receptors after chronic nicotine or oxotremorine. Pharmacol Biochem Behav 1985; 22:283-291. (Pubitemid 15132114)
4. Mc Callum SE, Caggiula AR, Epstein LH, Saylor S, Ploskina T, Sved AF. Mecamylamine blocks the development oftolerance to nicotine in rats: implications for the mechanisms of tolerance. Psychopharmacology 1999; 141:332-338. (Pubitemid 29196084)
5. Yang C-Y, Wu W-H, Zbuzek VK. Antinociceptive effect of chronic nicotine and nociceptive effect of its withdrawal measured by hot-plate and tail-flick in rats. Psychopharmacology 1992; 106:417-420.
6. Carstens E, Anderson KA, Simons CT, Carstens MI, Jinks SL. Analgesia induced by chronic nicotine infusion in rats: differences by gender and pain test. Psychopharmacology (Berl) 2001; 157:40-45. (Pubitemid 32758957)
7. Jones PG, Dunlop J. Targeting the cholinergic system as a therapeutic strategy for the treatment of pain. Neuropharmacology 2007; 53:197-206. (Pubitemid 47187447)
8. Varney MA, Gereau RW IV. Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets CNS Neurol Disord 2002; 1:283-296.
9. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433:73-77. (Pubitemid 40101145)
10. Rasmussen BA, Baron DA, Kim JK, Unterwald EM, Rawls SM. ß-Lactam antibiotic produces a sustained reduction in extracellular glutamate in the nucleus accumbens of rats. Amino Acids 2011a; 40:761-764.
11. Hu Y, Li W, Lu L, Cai J, Xian X, Zhang M, et al. An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. Pain 2010; 148:284-301.
12. Rawls SM, Zielinski M, Patel H, Sacavage S, Baron DA, Patel D. Beta-lactam antibiotic reduces morphine analgesic tolerance in rats through GLT-1 transporter activation. Drug Alcohol Depend 2010; 107:261-263.
13. Gunduz O, Oltulu C, Ulugol A. Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the beta-lactam antibiotic, ceftriaxone, in mice. Pharmacol Biochem Behav 2011a; 99:100-103.
14. Gunduz O, Oltulu C, Buldum D, Guven R, Ulugol A. Anti-allodynic and anti hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett 2011b; 491:23-25.
15. Tripathi HL, Martin BR, Aceto MD. Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J Pharmacol Exp Ther 1982; 221:91-96. (Pubitemid 12156477)
16. Liechti ME, Markou A. Role of the glutamatergic system in nicotine dependence: implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs 2008; 22: 705-724.
17. Iwamoto ET. Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. J Pharmacol Exp Ther 1991; 257:120-133.
18. Inglis WL, Semba K. Colocalization of ionotropic glutamate receptor subunitswith NADPH-diaphorase-containing neurons in the rat mesopontine tegment. J Comp Neurol 1996; 368:17-32.
19. Lai YY, Clements JR, Siegel JM. Glutamatergic and cholinergic projections to the pontine inhibitory area identified with horseradish peroxidase retrograde transport and immunohistochemistry. J Comp Neurol 1993; 336:321-330. (Pubitemid 23294114)
20. Beitz AJ. Relationship of glutamate and aspartate to the periaqueductal gray-raphe magnus projection: analysis using immunocytochemistry and microdialysis. J Histochem Cytochem 1990; 38:1755-1765. (Pubitemid 20382391)
21. Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry 2010; 67:81-84.
22. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Science 2008; 153:329-337
23. Rawls SM, Tallarida R, Robinson W, Amin M. The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats. Br J Pharmacol2007; 151:1095-1102. (Pubitemid 47195525)
24. Rasmussen B, Unterwald EM, Rawls SM. Glutamate transporter subtype 1 (GLT-1) activator ceftriaxone attenuates amphetamine-induced hyperactivity and behavioral sensitization in rats. Drug Alcohol Depend 2011; 118: 484-488.